Barcode Diagnostics: Nanotechnology Aided Personalized Cancer MedicineRonen Eavri, CEO - Barcode Diagnostics Over 1.6M new cancer cases are diagnosed in the US each year. Based on current literature, one of three patients does not receive the optimal treatment he or she deserves. Today, once a tumor is diagnosed, choice of treatment based on clinical signs manifested in similar cancer cases which result in trial and error of multiple chemotherapy regimens. Beyond the loss of valuable time and suffering for each patient, the financial burden of the wrong treatment choice accounts for more than $10B in direct costs annually in the US alone. To overcome this huge unmet need, emerging sequence-based treatments offer a new hope for patients, yet these technologies still lack in their ability to predict the optimal treatment choice for each patient. |
|
Organized & Produced by: |
POB 4043, Ness Ziona 70400, Israel |